As litigation over a diabetes drug that allegedly causes heart problems winds down, drugmaker GlaxoSmithKline won summary judgment in the latest Avandia case originally scheduled to go to trial in Philadelphia Common Pleas Court this week.
The summary judgment ruling by Common Pleas Judge Sandra Mazer Moss, coordinating judge of Philadelphia’s mass torts program, the Complex Litigation Center, is unusual because most of the Avandia cases pending in Pennsylvania state court have settled before significant rulings were issued. And no trials have yet been held in state court during the course of the litigation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
